Review Article

Different effects of prolonged β-adrenergic stimulation on heart and cerebral artery

Eunji Shin, Kyung Soo Ko, Byoung Doo Rhee, Jin Han, Nari Kim

National Leading Research Laboratory for Innovative Cardiovascular Engineering, Cardiovascular and Metabolic Disease Center, Inje University, Busan, Korea

Abstract

The aim of this review was to understand the effects of β-adrenergic stimulation on oxidative stress, structural remodeling, and functional alterations in the heart and cerebral artery. Diverse stimuli activate the sympathetic nervous system, leading to increased levels of catecholamines. Long-term overstimulation of the β-adrenergic receptor (βAR) in response to catecholamines causes cardiovascular diseases, including cardiac hypertrophy, stroke, coronary artery disease, and heart failure. Although catecholamines have identical sites of action in the heart and cerebral artery, the structural and functional modifications differentially activate intracellular signaling cascades. βAR-stimulation can increase oxidative stress in the heart and cerebral artery, but has also been shown to induce different cytoskeletal and functional modifications by modulating various components of the βAR signal transduction pathways. Stimulation of βAR leads to cardiac dysfunction due to an overload of intracellular Ca²⁺ in cardiomyocytes. However, this stimulation induces vascular dysfunction through disruption of actin cytoskeleton in vascular smooth muscle cells. Many studies have shown that excessive concentrations of catecholamines during stressful conditions can produce coronary spasms or arrhythmias by inducing Ca²⁺-handling abnormalities and impairing energy production in mitochondria. In this article, we highlight the different fates caused by excessive oxidative stress and disruptions in the cytoskeletal proteome network in the heart and the cerebral artery in response to prolonged βAR-stimulation.

© 2014 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Chronic increased sympathetic activation occurs in many situations, including obesity, sleep apnea, mental stress, and hypertension, promoting the development of cardiovascular diseases through sustained stimulation of adrenergic receptors.1-4 These fatal cardiac events include cardiac hypertrophy, heart failure, and sudden cardiac death.5-9 Elevated levels of catecholamines stimulate the α-adrenergic receptor and β-adrenergic receptor (βAR); however, most of the adverse cardiac effects associated with increased sympathetic tone on the heart have been believed to be caused mostly by
stimulation of \( \beta \text{AR} \) in the heart. In fact, \( \beta \text{AR} \) blockade consistently improves cardiac function and survival in patients with heart failure.\(^{10,11}\) By contrast, \( \alpha \)-adrenergic receptor blockades is an effective anti-hypertensive approach, but may actually increase the risk of cardiovascular events, as shown in patients taking doxazosin in the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).\(^{12}\) Use of the \( \beta \text{AR} \) blocker metoprolol during the periperoic period in patients with non-cardiac diseases was associated with an increased risk of strokes and death.\(^{13}\) These studies suggest that sympathetic agents are unlikely to be accepted as a common regimen for the treatment of both the heart and the vasculature simultaneously. Based on these findings, over-stimulation of \( \beta \text{AR} \) appears to have different effects on the heart and cerebral artery. Therefore, the focus of this review is to compare cardiac and vascular, effects of beta AR stimulation and effects on related signal transduction processes.

2. Effect of prolonged \( \beta \text{AR} \) stimulation on the heart

Long-term \( \beta \text{AR} \) activation by various stressors induces serious myocardial damages, including cardiac hypertrophy, necrosis/apoptosis, and fibrosis.\(^{7,9,14-16}\) Cardiac hypertrophy is an independent cause of heart failure and major cause of morbidity and mortality throughout the world; thus, research and clinical interventions for cardiac hypertrophy have been extensively studied.\(^{17-19}\)

Once cardiac hypertrophy develops, it progresses to heart failure.\(^{17}\) The underlying mechanisms associated with \( \beta \text{AR} \) overstimulation have been studied in vivo in heart tissue using isoproterenol (ISO)-treated models and in vitro in cultured cardiomyocytes. This \( \beta \text{AR} \) overstimulation represents an important hallmark of pathologic cardiac hypertrophy.\(^{15,20-24}\)

ISO treatment increases oxidative stress, protein synthesis, proto-oncogene expression, and stimulation of mitogen-activated protein kinases. These events are caused by altered electrical and mechanical capabilities that induce three modes of cell death: necrosis, apoptosis, and autophagy (see Table 1).

Furthermore, ISO treatment alters related signal transduction pathways. In the normal heart, \( \beta \text{AR} \) activation stimulates adenylyl cyclase activity via \( \text{Gs} \) protein-coupled receptors, which leads to the formation of \( \text{cAMP} \). Increased \( \text{cAMP} \) elevates intracellular concentrations of \( \text{Ca}^{2+} \), which activates protein kinase A (PKA)-mediated phosphorylation of different \( \text{Ca}^{2+} \)-handling proteins, producing positive inotropic effects in the heart. However, long-term ISO stimulation results in desensitization of the PKA-dependent receptor after previous phosphorylation, thus attenuating \( \beta \text{AR} \)-mediated response.\(^{15,25,26}\)

Tse et al\(^{26}\) showed that cardiac hypertrophy develops in rats treated chronically with ISO stimulation; further, these rats showed decreased magnitude and sensitivity of contractility in vitro in response to ISO stimulation. These effects were, related to biochemical alterations, including decreased numbers of \( \beta \text{ARs} \), decreased sensitivity and magnitude of adenylyl cyclase activity, and decreased \( \text{cAMP} \) formation. We also clearly showed that PKA activity, but not protein kinase C (PKC) activity, in the rabbit heart decreased gradually with time after prolonged \( \beta \text{AR} \) stimulation.\(^{15}\) In addition to the study of Tse et al,\(^{26}\) underlying mechanisms of \( \beta \text{AR} \) desensitization to an agonist may be associated with an increased \( \beta \text{AR} \) kinase activity.\(^{27}\) This possibility is supported by the finding that \( \beta \text{AR} \) stimulation can significantly increase the expression of \( \beta \text{AR} \) kinase 1, whereas \( \beta \text{AR} \) blockade decreases the expression.\(^{28}\)

3. Effect of prolonged \( \beta \text{AR} \) stimulation on the vasculature

Despite massive studies on the effects of ISO treatment on the heart, few studies have been performed to evaluate its effects on the vasculature. Pathological cardiac hypertrophy caused by overstimulation of \( \beta \text{AR} \) is a potent, independent predictor of cerebrovascular events such as stroke.\(^{29,30}\)

In diverse vessels, such as the femoral, pulmonary, and carotid arteries, acute stimulation of \( \beta \text{AR} \) induces vasodilation.\(^{31}\) Long-term stimulation of \( \beta \text{AR} \) in arteries, however, can induce alterations in vascular contractility.

Previously, we demonstrated that prolonged ISO treatment in rabbits leads to abnormalities in the coronary arterial functions through alterations in the \( \text{Ca}^{2+} \)-activated K+ and inward-rectifier K+ channels in smooth muscle cells. This implies a novel mechanism for vascular dysfunction during cardiac hypertrophy.\(^{14,32}\) With regard to the rat aorta, Davel et al\(^{33}\) demonstrated that prolonged ISO stimulation induced endothelial dysfunction and increased vasoconstriction by phenylephrine, an \( \alpha \)-adrenergic receptor agonist, due to endothelial dysfunction. They suggested that ISO treatment enhanced the vasoconstrictor response and increased oxidative stress via Endothelial Nitric Oxide Synthase (eNOS) uncoupling, through the \( \beta \text{AR}/\text{G}\alpha \) signaling pathway.\(^{34}\) Interestingly, we found that \( \beta \text{AR} \) stimulation decreased transient \( \text{Ca}^{2+} \) efflux and attenuated contraction in response to angiotensin II in the rabbit cerebral artery.\(^{35}\) Possible mechanisms of abnormal response to vasoactivity in different arteries may be due to factors other than biochemical alterations, as shown in the heart. These include the possibility that vascular tissues are vulnerable to oxidative stress, which may disrupt the cytoskeleton further.\(^{35}\)

4. Differential modulation of the proteome in the heart and cerebral artery during \( \beta \text{AR} \) stimulation

To help improve interventions for managing cerebrovascular events during cardiac hypertrophy, here we focus on differences between cardiac and vascular signaling during prolonged \( \beta \text{AR} \) stimulation.

Inducible proto-oncogenes encode nuclear transcription factors and activate promoters of many target genes playing a that have roles in cellular functions, adaptive processes, or cell death.\(^{36-38}\) Prolonged \( \beta \text{AR} \) stimulation increases the phosphorylation of Extracellular signal-Regulated Kinase (ERK) increasing expression of \( \text{c-fos} \) and \( \text{c-myc} \) in the cerebral arteries, whereas only \( \text{c-fos} \) expression corresponds to the increased phosphorylation of ERK in the heart. Therefore,
Table 1 – Gene/protein expression profiles in heart and cerebral artery by prolonged βAR stimulation

| Identification and functional category | Heart | Cerebral artery | ref. |
|----------------------------------------|-------|----------------|-----|
|                                        | increase | decrease | increase | decrease | |
| Apoptosis/necrosis                      |         |           |         |           | |
| Bcl2l1       | Bcl-2-like-protein 1 (Bcl-XL) | + | 54 | |
| Bcl2li1      | Bcl-2-like protein 11 | + | 54 | |
| Bmf          | Bcl-2 modifying factor | + | 54 | |
| Bax          | Bcl-2 antagonist | + | 54 | |
| Pmaip1       | Phorbol-12-myristate-13-acetate-induced protein 1 | + | 54 | |
| Sfn          | Stratafin | – | 54 | |
| Tp53         | Tumor protein 53 (p53) | – | 54 | |
| Apaf1        | Apoptotic protease activating factor 1 | + | 54 | |
| Casp1        | Caspase-1 | + | 54 | |
| Casp2        | Caspase-2 (initiator) | + | 54 | |
| Casp3        | Caspase-3 (effector) | + | 54 | |
| Casp7        | Caspase-7 (effector) | – | 54 | |
| Casp9        | Caspase-9 (initiator) | + | 54 | |
| Tnfrsf1a     | Tumor necrosis factor receptor superfamily 1A | + | 54 | |
| Tnfsf10      | Tumor necrosis factor (ligand) superfamily, 10 | + | 54 | |
| Fas          | Tumor necrosis factor receptor superfamily 6 | + | 54 | |
| Stress/energy |         |           |         |           | |
| Abcb4        | ATP-binding cassette, subfamily B (MDR/TAP) 1A | + | 54 | |
| Abcc3        | ATP-binding cassette protein C3 | – | 54 | |
| Ahr          | Aryl-hydrocarbon receptor | + | 54 | |
| Akt          | Akt | – | 54 | |
| ALDH1A1      | Aldehyde dehydrogenase, family 1 member A1 | – | 35 | |
| ALDH2        | Aldehyde dehydrogenase, mitochondrial precursor | + | 35 | |
| ANX6         | Annexin VI isoform 1 | + | 35 | |
| ANXA1        | Annexin A1 (annexin I) | + | 35 | |
| ARH          | ADP-ribosehydrolase | + | 55 | |
| Arnt2        | Aryl-hydrocarbon receptor nuclear translocator 2 | + | 54 | |
| ATP5b        | ATP synthase subunit β, mitochondrial precursor | + | 55 | |
| Bcat1        | Branched chain amino acid transaminase 1 | + | 54 | |
| Ccct2        | Chaperonin containing TCP1, subunit 2 (beta) | + | 35 | |
| DPYSL2       | Dihydropyrimidinase-like2 | + | 35 | |
| EARH         | Ecto ADP-ribosehydrolase precursor | + | 55 | |
| EARH         | Ecto ADP-ribosehydrolase precursor | + | 55 | |
| EF1G         | Elongation factor 1-gamma | + | 35 | |
| GDI2         | GDP dissociation inhibitor 2 | + | 35 | |
| GLUD1        | Glutamate dehydrogenase | + | 35 | |
| GSTM5        | Glutathione-S-transferase, mu5 | + | 35 | |
| Hif1an       | Hypoxia-inducible factor 1-alpha inhibitor | – | 54 | |
| Hif3a        | Hypoxia-inducible factor 3-alpha | + | 54 | |
| Hsp          | Heart shock protein 75 kDa | – | 55 | |
| Hsp11L       | Heat shock 70 kDa, protein 1-like | – | 54 | |
| Hspb7        | Heat shock 27 kDa, cardiovascular | + | 54 | |
| Hspa2        | Heat shock 70 kDa, protein 2 | + | 54 | |
| Hspa5        | Heat shock 70 kDa, protein 5 | – | 54 | |
| Hspa8        | Heat shock 70 kDa, protein 8 (Hsp73) | – | 54 | |
| Hspa9        | Heat shock protein 9A, mortalin | + | 35 | |
| IDH1         | Isocitrate dehydrogenase 1 (NADP+) | + | 35 | |
| Lamc         | Isoform C of lamin-A/C | – | 55 | |
| NDUF51       | NADH dehydrogenase (ubiquinone) Fe–S protein 1 | + | 35 | |
| NDUF58       | NADH dehydrogenase (ubiquinone) Fe–S protein 8 | + | 35 | |
| Nos2         | Nitric oxide synthase, inducible | – | 54 | |
| Ntrb4        | Nuclear receptor subfamily 1, group H, member 4 | – | 54 | |
| OTUB1        | Ubiquitin thioesterase protein OTUB1 | + | 55 | |
| Pdia3        | Protein disulfide isomerase family A, member 3 | – | 35 | |
| PEA15        | Isoform 1 of astrocytic phosphoprotein PEA-15 | + | 55 | |
| Pparγ        | Peroxisome proliferator-activated receptor gamma | – | 54 | |
| Pparα        | PPAR α | – | 54 | |
| Ppalase      | Peptidyl-prolyl cis-trans isomerase E | – | 55 | |
| RALDH2       | Aldehyde dehydrogenase 1A2 isoform 1 | + | 35 | |
| RanGAP       | Ran-specific GTPase-activating protein | + | 55 | |
post-translational modulation appears to progress via different mechanisms in the heart and the cerebral artery.

Although cardiac hypertrophy is not known to be a prerequisite for altered expression of proto-oncogenes in vivo, βAR stimulates Gβ-dependent PI3 kinase (PI3K) activity and cell growth. In human erythroid progenitors cells, PKC and PI3K pathways are parallel and converge to activate the c-fos and c-myc genes.

In addition, decreased signaling of the Ras/Raf/MEK/ERK cascade in the cerebral artery during cardiac hypertrophy can interrupt the actin cytoskeletal network, because Ras/Raf/MEK/ERK is essential for actin-base cytoskeletal organization. In contrast, Ras and Raf are activated in the heart during cardiac hypertrophy, and may roles in proliferation and transformation. Decreased PKA activity may possibly contribute indirectly to decreased expressions of the Ras/Raf/MEK/ERK signaling in the cerebral artery, because PKA activity is well known to innately correspond with Ras/Raf activation. However, recent findings also demonstrated that PKA activation does not contribute to Ras/Raf activation. Thus we suggested that the underlying mechanism of vascular dysfunction resulting from the decreased expression levels of RhoA and ROCK1 proteins after βAR stimulation. RhoA and ROCK1 are involved in actin-cytoskeletal organization and phosphorylation of myosin light chain producing smooth muscle contraction. The contractility of vascular smooth muscle cells is widely regulated by the cytoskeletal proteome network. Our previous study clearly shows that βAR stimulation disrupts the actin cytoskeletal proteome network through downregulation of RhoA/ROCK1 proteins attenuating angiotensin II-induced contraction in the cerebral artery.

Cardiac or cerebral remodeling by βAR stimulation may involve changes in cellular energy. However, there are a few studies of proteome analysis of βAR stimulated pathways in the heart and the cerebral artery; these studies, revealed...
similarities in the main response, including apoptosis/necrosis, stress/energy, inflammation, and remodeling/fibrosis (also see Table 1). In the heart, a greater number of genes are altered in the category of energy or remodeling, whereas, a greater number of genes involved in cytoskeletal organization are altered in the cerebral artery.

Regarding oxidative stress, expression levels of several cytoprotective chaperones and protein maturation elements are significantly decreased in both the heart and the cerebral artery. Excessive levels of reactive oxygen species (ROS) results in oxidative stress, because the balance between production of ROS and activation of the antioxidant system is essential for controlling homeostasis. Sustained high levels of circulating catecholamines induced by stress can result in cardiotoxicity due to the production of oxygen free radicals. This is supported by several recent findings demonstrating that βAR stimulation increase ROS production in the HEK293 cells, rat cardiac myocytes, and the rat aorta. Increased oxidative stress can also lead to DNA damage. Interestingly, in either the heart or the cerebral artery, decreased levels of cytoprotective proteins, including heat shock protein 70/90 and stress-induced-phosphoprotein 1, are more likely due to cause deleterious effects - rather than increased ROS production. Heat shock proteins are crucial to cellular defense and mitochondrial protection against oxidative stress; these are ubiquitous and highly conserved chaperones are associated with myocardial protection. Oxidative stress activates several kinase signaling pathways, such as PKC, Mitogen-activated protein kinases (MAPK), and PI3K.

In particular, the Bcl-2 like protein 1 and Bak1, which are associated with mitochondria, are significantly altered in the heart. These proteins induce apoptosis by regulating metabolite diffusion across the outer mitochondrial membrane. Apoptosis during cardiac hypertrophy caused by βAR stimulation is of particular interest, as recent literature indicates that deterioration of the hypertrophied heart is linked to progressive loss of cardiomyocytes. Other groups have also shown that inhibition of apoptosis is accompanied by attenuation of heart failure and cardiac hypertrophy, along with increased cardiomyocyte apoptosis prior to the development of significant heart failure. Taken together, modulation of apoptosis during cardiac hypertrophy as a preventive for heart failure or stroke may lead to viable therapeutic modalities in the near future.

5. Conclusion

Epinephrine and norepinephrine injections stimulate αAR and βAR can cause cardiac cell damage to a qualitatively similar extent. In contrast, ISO injection stimulates only βAR can impair the myocardium more severely. Therefore, most of the studies have focused on understanding βAR-mediated signal transduction mechanisms and finding targets to prevent βAR-mediated cardiac remodeling. More recently, βAR overstimulation of vascular structural and function has shown differential effects compared to that of the heart. Therefore, cerebrovascular remodeling and dysfunction reviewed in this study may give a new insight into understanding cerebral damage after βAR overstimulation, during long-term stress and therapeutic intervention of βAR overstimulation induced cardiovascular events.

Conflicts of interest

There are no conflicts of interest.

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF), and funding was granted by the Ministry of Science, ICT & Future Planning of Korea (2011-0028925 and 2012R1A2A1A03007595) and by the Ministry of Education of Korea (2010-0020224).

REFERENCES

1. Esler M, Jennings G, Biviano B, Lambert G, Hasking G. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986;8(Suppl 5):S39–43.
2. Esler MD, Eikelis N, Lambert E, Straznicky N. Neural mechanisms and management of obesity-related hypertension. Curr Cardiol Rep 2008;10:456–63.
3. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreflex sensitivity in obstructive sleep apnea. Circulation 1999;99:1183–9.
4. Neumann SA, Jennings JR, Muldoon MF, Manuck SB. White-coat hypertension and autonomic nervous system dysregulation. Am J Hypertens 2005;18:584–8.
5. Davis AM, Natelson BH. Brain–heart interactions. The neurocardiology of arrhythmia and sudden cardiac death. Tex Heart Inst J 1993;20:158–69.
6. Dunn FG, Pringle SD. Sudden cardiac death, ventricular arrhythmias and hypertensive left ventricular hypertrophy. J Hypertens 1993;11:1003–10.
7. Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res 1994;28:933–46.
8. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561–6.
9. Osadchii OE. Cardiac hypertrophy induced by sustained beta-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 2007;12:66–86.
10. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184–91.
11. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807–16.
12. Davis BR, Cutler JA, Furberg CD, Wright JT, Farber MA, Felicetta JV, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med 2002;137:313–20.
13. POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839–47.

14. Kim N, Chung J, Kim E, Han J. Changes in the Ca2+-activated K+ channels of the coronary artery during left ventricular hypertrophy. Circ Res 2003;93:541–7.

15. Kim N, Kim H, Youm JB, Park WS, Warda M, Ko JH, et al. Site specific differential activation of ras/raf/ERK signaling in rabbit isoproterenol-induced left ventricular hypertrophy. Biochim Biophys Acta 2006;1763:1067–75.

16. Zheng M, Zhu W, Han Q, Xiao R. Emerging concepts and therapeutic implications of beta-adrenergic receptor subtype signaling. Pharmacol Ther 2005;108:257–68.

17. Diwan A, Dorn 2nd GW. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) 2007;22:56–64.

18. Gupta S, Das B, Sen S. Cardiac hypertrophy: mechanisms and therapeutic opportunities. Antioxid Redox Signal 2007;9:623–52.

19. Kang YJ. Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol 2006;34:58–66.

20. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, Garner HR. Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther 2008;324:1194–203.

21. Freund C, Schmidt-Ullrich R, Baurand A, Dunger S, Metrich M, Lucas A, Gastineau M, Samuel JL, Heymes C, et al. Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ Res 2008;102:959–65.

22. Hanada K, Asari K, Saito M, Kawana J, Mita M, Ogata H. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. Br J Pharmacol 2006;148:629–39.

23. Hayes JS, Wyss VL, Schenck KS, Cohen ML. Effects of prolonged isoproterenol infusion on cardiac and vascular responses to adrenocortical agonists. J Pharmacol Exp Ther 1986;237:757–63.

24. Iaccarino G, Tomhave ED, LeFkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 1998;98:1783–9.

25. Iaccarino G, Tomhave ED, LeFkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 1998;98:1783–9.

26. Choi DJ, Koch WJ, Hunter JJ, Rockman HA. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. J Biol Chem 1997;272:17223–9.

27. Contard F, Glukhova M, Marotte F, Narcisse G, Schatz C, Swyngedauw B, et al. Diuretic effects on cardiac hypertrophy in the stroke prone spontaneously hypertensive rat. Cardiovasc Res 1993;27:429–34.

28. Rodrigo C, Weerasinge S, Jeevagan V, Rajapakse S, Constantine G. Addressing the relationship between cardiac hypertrophy and ischaemic stroke: an observational study. Int Arch Med 2012;5:5. Article number 32.

29. Chruscińska A, Brede ME, Meinel L, Lohse MJ, Kobilka BK, Hein L. Differential distribution of beta-adrenergic receptor subtypes in blood vessels of knockout mice lacking beta(1)- or beta(2)-adrenergic receptors. Mol Pharmacol 2003;60:955–62.

30. Piszczek A, Brede ME, Meinel L, Lohse MJ, Kobilka BK, Hein L. Differential distribution of beta-adrenergic receptor subtypes in blood vessels of knockout mice lacking beta(1)- or beta(2)-adrenergic receptors. Mol Pharmacol 2003;60:955–62.

31. Park WS, Ko JH, Kim N, Son YK, Kang SH, Warda M, et al. Increased inhibition of inward rectifier K+ channels by angiotensin II in small-diameter coronary artery of isoproterenol-induced hypertrophied model. Arterioscler Thromb Vasc Biol 2007;27:1768–75.

32. Davel AP, Kawamoto EM, Scavone C, Vassallo DV, Rossoni LV. Changes in vascular reactivity following administration of isoproterenol for 1 week: a role for endothelial modulation. Br J Pharmacol 2006;148:629–39.

33. Davel AP, Brum PC, Rossoni LV. Isoproterenol induces vascular oxidative stress and endothelial dysfunction via a Gialpha-coupled beta2-adrenergic receptor signaling pathway. PLoS One 2014;9:e91877.

34. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstok KL, et al. Nucleus tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1999;101:1–28.

35. Edwards M, Preston K. The role of inducible transcription factors in apoptotic nerve cell death. Brain Res Brain Res Rev 1995;21:1–28.

36. Hughes P, Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol Rev 1995;47:133–78.

37. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstok KL, et al. Nucleus tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1999;101:1–28.

38.contrast with the expression of caudal homeobox gene Cdx-2 by cyclic AMP.

39. Krown KA, Page MT, Nguyen C, Zechner D, Gutierrez V, Comstok KL, et al. Nucleus tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1999;101:1–28.

40. Chesley A, Lundberg MS, Asai T, Xiao RP, Ohtani S, Lakatta EG, et al. The beta(2)-adrenergic receptor delivers an antipapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res 2000;87:1172–9.

41. Schmidt EK, Fichelson S, Feller SM. PI3 kinase is important for Ras, MEK and Erk activation of Epo-stimulated human erythroid progenitors. BMC Biol 2004;2:12. Article number 7.

42. Pozzi A, Coiffa S, Bulus N, Zhu W, Chen D, Chen X, et al. H-Ras, R-Ras, and TC21 differentially regulate ureteric bud cell branching morphogenesis. Mol Biol Cell 2006;17:2046–56.

43. Tanaka Y, Minami Y, Mine S, Hirano H, Hu CD, Fujimoto H, et al. H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. J Immunol 1999;163:6209–16.

44. Zimmer HG. Catecholamine-induced cardiac hypertrophy: significance of proto-oncogene expression. J Mol Med (Berl) 1997;75:849–59.

45. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Mol Immunol 1997;34:133–57.

46. Chen L, Wang P, Andrade CF, Zhao IY, Dubé PE, Brubaker PL, et al. PKA independent and cell type specific activation of Ras, MEK and Erk expression within the nervous system. Mol Immunol 1997;34:133–57.
smooth muscle contraction through myosin light chain 
phosphorylation. J Biol Chem 1997;272:12257–60.
48. Gunst SJ, Zhang W. Actin cytoskeletal dynamics in smooth 
muscle: a new paradigm for the regulation of smooth 
muscle contraction. Am J Physiol Cell Physiol 2008;295: 
C576–87.
49. Remiao F, Carmo H, Carvalho FD, Bastos ML. Inhibition of 
glutathione reductase by isoproterenol oxidation products. J 
Enzyme Inhib 2000;15:47–61.
50. Moniri NH, Daaka Y. Agonist-stimulated reactive oxygen 
species formation regulates beta2-adrenergic receptor signal 
transduction. Biochem Pharmacol 2007;74: 
64–73.
51. Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer 
DB, Singh K, et al. Beta-adrenergic receptor-stimulated 
apoptosis in cardiac myocytes is mediated by reactive 
oxygen species/c-Jun NH2-terminal kinase-dependent 
activation of the mitochondrial pathway. Circ Res 
2003;92:136–8.
52. Davel AP, Fukuda LE, De Sa LL, Munhoz CD, Scavone C, 
Sanz-Rosa D, et al. Effects of isoproterenol treatment for 7 
days on inflammatory mediators in the rat aorta. Am J 
Physiol Heart Circ Physiol 2008;295:H211–9.
53. Keles MS, Bayir Y, Suleyman H, Halici Z. Investigation of 
effects of lacidipine, ramipril, and valsartan on DNA damage 
and oxidative stress occurred in acute and chronic periods 
following isoproterenol-induced myocardial infarct in rats. 
Mol Cell Biochem 2009;328:109–17.
54. Herrmann JE, Heale J, Bieraugel M, Ramos M, Fisher RL, 
Vickers AE. Isoproterenol effects evaluated in heart slices of 
human and rat in comparison to rat heart in vivo. Toxicol Appi 
Pharmacol 2014;274:302–12.
55. Hong HM, Song EJ, Oh E, Kabir MH, Lee C, Yoo YS. 
Endothelin-1- and isoproterenol-induced differential protein 
expression and signaling pathway in HL-1 cardiomyocytes. 
Proteomics 2011;11:283–97.
56. Martin JL, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann 
WH. Small heat shock proteins and protection against 
ischemic injury in cardiac myocytes. Circulation 
1997;96:4343–8.
57. Corbi G, Conti V, Russomanno G, Longobardi G, Furgi G, 
Filippelli A, et al. Adrenergic signaling and oxidative stress: a 
role for sirtuins? Front Physiol 2013;4:14. Article number 324.
58. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine 
phosphorylation of death agonist BAD in response to 
survival factor results in binding to 14-3-3 not BCL-X(L). Cell 
1996;87:619–28.
59. Yasuhara S, Zhu Y, Matsui T, Tipirneni N, Yasuhara Y, Kaneki 
M, et al. Comparison of comet assay, electron microscopy, 
and flow cytometry for detection of apoptosis. J Histochem 
Cytochem 2003;51:873–85.
60. Ratcliffe NR, Hutchins J, Barry B, Hickey WF. Chronic 
myocarditis induced by T cells reactive to a single cardiac 
myosin peptide: persistent inflammation, cardiac dilatation, 
myocardial scarring and continuous myocyte apoptosis. J Autoimmun 
2000;15:359–67.
61. Park SJ, Choi DJ, Kim CW. Hypertensive left ventricular 
hypertrophy: relation to beta-adrenergic receptor kinase-1 
(betaARK1) in peripheral lymphocytes. J Hypertens 
2004;22:1025–32.